|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
Hanfeng Pharmaceutical
|
|
gptkbp:awards
|
Best Biopharmaceutical Company
KOSDAQ 200 Index
|
|
gptkbp:ceo
|
gptkb:Soo-Young_Lee
|
|
gptkbp:clinical_trial
|
ongoing
Phase II
Phase III
Phase I
adalimumab biosimilar
infliximab biosimilar
trastuzumab biosimilar
|
|
gptkbp:employees
|
over 1,000
|
|
gptkbp:focus_area
|
biologics
therapeutics
biosimilar drugs
|
|
gptkbp:founded
|
gptkb:2002
|
|
gptkbp:founder
|
gptkb:Soo-Young_Lee
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:has_research_center
|
R& D center
biologics manufacturing plant
|
|
gptkbp:headquarters
|
gptkb:Incheon,_South_Korea
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Celltrion Healthcare
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:investment
|
clinical research
global expansion
biotechnology research
manufacturing capacity
|
|
gptkbp:market
|
global
|
|
gptkbp:part_of
|
Celltrion Group
|
|
gptkbp:partnership
|
gptkb:Eli_Lilly
gptkb:Merck
gptkb:GSK
gptkb:Johnson_&_Johnson
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Roche
gptkb:Amgen
gptkb:Samsung_Biologics
gptkb:Abb_Vie
gptkb:Novartis
|
|
gptkbp:products
|
monoclonal antibodies
biosimilars
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research_focus
|
oncology
autoimmune diseases
|
|
gptkbp:revenue
|
over $1 billion
|
|
gptkbp:stock_exchange
|
gptkb:KOSDAQ
|
|
gptkbp:subsidiary
|
Celltrion Inc.
Celltrion Pharm.
|
|
gptkbp:sustainability_initiatives
|
community engagement
ethical practices
environmental responsibility
|
|
gptkbp:website
|
www.celltrion.com
|
|
gptkbp:bfsParent
|
gptkb:Celltrion
|
|
gptkbp:bfsLayer
|
6
|